Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
نویسندگان
چکیده
منابع مشابه
Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
[This corrects the article DOI: 10.1371/journal.ppat.1005000.][This corrects the article DOI: 10.1371/journal.ppat.1005740.][This corrects the article DOI: 10.1371/journal.ppat.1005679.].
متن کاملHIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
Early stochastic events may play a role in delaying the time-to-detection of virus after an initial reactivation event. This may occur because, when there are only small numbers of infected cells, it is possible for the number of infected cells to expand, contract, or occasionally continue at low levels for some time before expanding (leading to a delay before exponential growth commences). Her...
متن کاملModeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5–8 Days
1 Kirby Institute for Infection and Immunity, UNSWAustralia, Sydney, Australia, 2 Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia, 3 The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia, 4 Department of Infectious Diseases, Alfred Hospital and Monash University, Melbour...
متن کاملHeat shock protein 90 controls HIV-1 reactivation from latency.
Latency allows HIV-1 to persist in long-lived cellular reservoirs, preventing virus eradication. We have previously shown that the heat shock protein 90 (Hsp90) is required for HIV-1 gene expression and mediates greater HIV-1 replication in conditions of hyperthermia. Here we report that specific inhibitors of Hsp90 such as 17-(N-allylamino)-17-demethoxygeldanamycin and AUY922 prevent HIV-1 rea...
متن کاملCombinatorial latency reactivation for HIV-1 subtypes and variants.
The eradication of HIV-1 will likely require novel clinical approaches to purge the reservoir of latently infected cells from a patient. We hypothesize that this therapy should target a wide range of latent integration sites, act effectively against viral variants that have acquired mutations in their promoter regions, and function across multiple HIV-1 subtypes. By using primary CD4(+) and Jur...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: PLOS Pathogens
سال: 2016
ISSN: 1553-7374
DOI: 10.1371/journal.ppat.1005745